915307-81-2Relevant articles and documents
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)
Chekol, Rufael,Gheysens, Olivier,Ahamed, Muneer,Cleynhens, Jan,Pokreisz, Peter,Vanhoof, Greet,Janssens, Stefan,Verbruggen, Alfons,Bormans, Guy
, p. 486 - 496 (2017/04/26)
The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies including pulmonary arterial hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or prognostic targ
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system
Hughes, Robert O.,Walker, John K.,Cubbage, Jerry W.,Fobian, Yvette M.,Rogier, D. Joseph,Heasley, Steve E.,Blevis-Bal, Rhadika M.,Benson, Alan G.,Owen, Dafydd R.,Jacobsen, E. Jon,Freskos, John N.,Molyneaux, John M.,Brown, David L.,Stallings, William C.,Acker, Brad A.,Maddux, Todd M.,Tollefson, Mike B.,Williams, Jennifer M.,Moon, Joseph B.,Mischke, Brent V.,Rumsey, Jeanne M.,Zheng, Yi,MacInnes, Alan,Bond, Brian R.,Yu, Ying
scheme or table, p. 4092 - 4096 (2010/03/30)
Efforts to improve the potency and physical properties of the aminopyridiopyrazinone class of PDE5 inhibitors through modification of the core ring system are described. Five new ring systems are evaluated and features that impart improved potency and imp
PYRIDINE [3,4-B] PYRAZINONES
-
, (2010/11/25)
Compounds, tautomers of the compounds, and pharmaceutically acceptable salts of the compounds or tautomers are disclosed, wherein the compounds have the structure of Formula I: wherein R2, X6, Y6, R6, and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.
